Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has scheduled its first quarter 2025 financial results announcement for Monday, May 12, 2025. The company will host a conference call and audio webcast at 4:30 p.m. ET to discuss financial results and provide company updates.

Investors can access the conference call via phone at (800) 836-8184 (local) or (646) 357-8785 (international). A live audio webcast with accompanying slides will be available on the company's investor relations website, with an archived version accessible approximately two hours after the event.

-- Conference Call Scheduled for Monday, May 12, 2025, at 4:30 p.m. ET --

NEWTON, Mass., May 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2025 financial results on Monday, May 12, 2025. Karyopharm's management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, May 12, 2025, to discuss the financial results and other company updates.

To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first­in­class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex­U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-report-first-quarter-2025-financial-results-on-may-12-2025-302450543.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When will Karyopharm (KPTI) report Q1 2025 earnings?

Karyopharm will report its Q1 2025 earnings on Monday, May 12, 2025, at 4:30 p.m. ET.

How can I access Karyopharm's Q1 2025 earnings call?

You can access the call by dialing (800) 836-8184 (local) or (646) 357-8785 (international), or via webcast on the company's investor website.

Where can I find the webcast of KPTI's Q1 2025 earnings call?

The webcast will be available under 'Events & Presentations' in the Investor section at http://investors.karyopharm.com/events-presentations

What does Karyopharm Therapeutics (KPTI) do?

Karyopharm Therapeutics is a commercial-stage pharmaceutical company that develops novel cancer therapies.